GxP Insights

Pharmaceutical Serialization: FMD and DSCSA Regulations

Pharmaceutical serialization and the regulations behind it: the EU FMD Directive 2011/62/EU and Delegated Regulation (EU) 2016/161, the unique identifier and anti-tampering device, and verification through EMVS and NMVS. With D.Lgs. 10/2025 Italy closed its bollino derogation: the stabilization period ends on 8 February 2027. Plus a side-by-side comparison with the US DSCSA.

G GuideGxP 5 min read
✓ Official sources and references ✓ Practical approach ✓ For pharmaceutical professionals
GUIDEGXP · PRACTICAL GMP INSIGHTS
Illustrazione editoriale GuideGxP a colori sul tema GMP: serializzazione dei farmaci, Data Matrix e tracciabilità della supply chain.

Pharmaceutical serialization is governed by regulations built on two pillars: in Europe, Directive 2011/62/EU — the Falsified Medicines Directive (FMD) — implemented through Delegated Regulation (EU) 2016/161; in the United States, the Drug Supply Chain Security Act (DSCSA). The goal is the same — keeping falsified medicines out of the legal supply chain — but the two models work differently. For Italy, 2025 marked the turning point: Legislative Decree 10/2025 ended the six-year derogation tied to the national bollino sticker and opened a stabilization period running until 8 February 2027. This guide gives you the up-to-date regulatory picture, the operational obligations along the supply chain and the deadlines to watch.

Pharmaceutical serialization regulations in the EU: FMD and Regulation 2016/161

Directive 2011/62/EU amends the Community code on medicinal products for human use (Directive 2001/83/EC) and introduces mandatory "safety features" on the packs of medicines most at risk of falsification. The operational rules come with Delegated Regulation (EU) 2016/161, applicable since 9 February 2019 across most of the Union: from that date, prescription medicines (except the exemptions listed in Annex I of the regulation) and certain non-prescription medicines considered at risk of falsification (Annex II) may only be placed on the market if serialized. The regulation also establishes the repositories system that makes verification possible and the obligations of the different actors: manufacturers, wholesalers and persons authorized to supply medicines to the public.

What goes on the pack: unique identifier and anti-tampering device

The safety features required by the EU regulation are two:

  • Unique identifier (UI): encoded in a two-dimensional Data Matrix and also printed in human-readable format. It contains the product code, a randomized serial number (maximum 20 characters), the batch number, the expiry date and, where the Member State requires it, the national reimbursement or identification number.
  • Anti-tampering device (ATD): a device allowing verification that the pack has not been opened or altered after packaging.

The unique identifier is applied during manufacturing and must not compromise the legibility of the mandatory labeling information: this is why artwork updates are almost always the first workstream of a serialization project, together with the qualification of printing and vision systems on packaging lines.

Deadlines like 8 February 2027 should not be managed at the last minute: subscribers to The Pragmatic GMP, GuideGxP's free weekly newsletter, get a practical update every week on GMP, GDP and regulatory changes like this one — based on primary sources, no fluff. Subscribe now.

How verification works: EMVS, NMVS and decommissioning

The European model is end-to-end, with verification at both ends of the chain. The manufacturer or marketing authorization holder uploads serialization data to the European hub managed by EMVO (European Medicines Verification Organisation), which routes them to the national repositories (NMVS) run by the national verification organisations. At the other end, the pharmacy or authorized facility verifies the authenticity of the identifier and decommissions it at the point of supply to the public. In between, wholesalers apply risk-based verification: among other things, they must check returns and medicines not received directly from the manufacturer or the MAH. Any abnormal verification outcome — a non-existent, already decommissioned or duplicated serial — triggers an alert that must be investigated as a potential falsification case, with the consequent impact on deviations and rapid alerts.

Italy after the derogation: D.Lgs. 10/2025 and stabilization until 2027

Italy, like Greece, already had a national traceability system based on the bollino farmaceutico sticker printed by the State Mint (Istituto Poligrafico e Zecca dello Stato), and therefore benefited from a six-year derogation from 2019. The derogation ended with Legislative Decree No. 10 of 6 February 2025 (Official Gazette No. 31 of 7 February 2025), which aligns national law with Regulation 2016/161. The key points:

  • on 9 February 2025 a 24-month stabilization period began, running until 8 February 2027, during which the bollino and the unique identifier may coexist on packs for the Italian market;
  • batches released by 9 February 2025 bearing only the bollino may be distributed and dispensed until their expiry date, without repackaging or relabeling;
  • medicines outside the scope of the EU regulation (most OTC and pharmacy-only products) continue to use the bollino farmaceutico;
  • the national verification repository is managed by the Italian NMVO, under the governance defined by the decree.

For manufacturing sites and Qualified Persons the transition is a project in its own right: new artwork with Data Matrix, qualification of printers and vision systems, onboarding to the EMVO hub, updated batch release procedures and management of the dual bollino/unique-identifier track in distribution.

DSCSA: the US model compared

In the United States, serialization is governed by the Drug Supply Chain Security Act (DSCSA, 2013), which pursues the same goal with a different architecture: not endpoint verification, but interoperable electronic tracing of transactions at the individual pack level, with data exchanged between trading partners at every change of ownership.

Aspect EU — FMD USA — DSCSA
Legal basis Directive 2011/62/EU + Delegated Regulation (EU) 2016/161 Drug Supply Chain Security Act (2013)
Approach End-to-end verification: data upload at manufacture, verification and decommissioning at dispensing Transactional track & trace: interoperable electronic exchange of transaction data (EPCIS standard)
Identifier Unique identifier in Data Matrix + anti-tampering device Product identifier (NDC, serial, lot, expiry) in Data Matrix
Data infrastructure EMVO European hub + national NMVS repositories No central database: data exchanged between trading partners
Implementation status In force since 2019; Italy in stabilization until 8 Feb 2027 Phased enforcement completed in 2025; small dispensers exempt until 27 Nov 2027

FDA phased in DSCSA enforcement: manufacturers and repackagers from May 2025, wholesale distributors from August 2025, large dispensers from November 2025. For "small dispensers" (pharmacies with 25 or fewer full-time pharmacists and technicians), on 6 August 2026 FDA extended the exemption from the enhanced requirements until 27 November 2027. Companies exporting to the US should therefore make sure today that their partners are ready for EPCIS data exchange.

GuideGxP recommendation

Treat serialization as a quality system requirement, not an IT project. In practice: map your portfolio by market (serialized EU, Italy on a dual track until 8 February 2027, US under DSCSA); plan the switch to Data Matrix well ahead of the end of the stabilization period, because the typical bottlenecks are artwork, vision equipment qualification and EMVO onboarding; and govern NMVS alert handling with a dedicated SOP, which inspectors read as a direct indicator of system maturity. If you work in distribution or manage the medicinal supply chain, GuideGxP's GDP Responsible Person (RP) — Operational Guide to Good Distribution Practice covers the quality system, traceability and supply chain obligations with ready-to-use, audit-defensible templates.

Frequently asked questions

Does serialization apply to all medicines?

No. Regulation 2016/161 covers prescription medicines (except the Annex I exemptions) and certain non-prescription medicines at risk of falsification (Annex II). In Italy, excluded medicines continue to use the bollino farmaceutico.

When does the transition period end in Italy?

The stabilization period under D.Lgs. 10/2025 ends on 8 February 2027. Batches released by 9 February 2025 with the bollino nevertheless remain saleable until their expiry date.

Is an FMD-compliant pack automatically DSCSA-compliant?

No. The two frameworks share the Data Matrix but differ in required data, architecture and transaction-data exchange obligations: the EU and US markets must be managed as separate requirements.

Official sources

THE PRAGMATIC GMP · EVERY MONDAY

The GMP topics that matter, in 7 minutes.

One GMP topic, one real-world example and one practical action, based on official sources and inspection trends.
Discover The Pragmatic GMP →